Christopher Thuring MD, Maria Carey MB BCh BAO, Timothy Webber MBBS, FCICM, Biswadev Mitra MBBS, MHSM, PhD, FACEM
{"title":"Therapeutic-dose verapamil-induced cardiogenic shock in an older patient: a case report","authors":"Christopher Thuring MD, Maria Carey MB BCh BAO, Timothy Webber MBBS, FCICM, Biswadev Mitra MBBS, MHSM, PhD, FACEM","doi":"10.1002/jppr.70091","DOIUrl":"https://doi.org/10.1002/jppr.70091","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Calcium channel blocker (CCB) toxicity most commonly follows deliberate overdose. However, severe toxicity at therapeutic doses may occur in susceptible individuals. Severe CCB toxicity often presents with clinical features of bradycardia, hypotension, hyperglycaemia, and lactic acidosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To highlight the potential for life-threatening cardiogenic shock from verapamil at therapeutic doses in susceptible individuals. Emphasise early recognition of the metabolic characteristics and haemodynamic features of CCBs, including reversibility with prompt, focused treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical details</h3>\u0000 \u0000 <p>An independent woman, aged in her 80s, with multiple cardiovascular comorbidities developed severe cardiogenic shock following an increase in dose of sustained-release verapamil for rapid atrial fibrillation during admission for presumed infective exacerbation of chronic obstructive pulmonary disease. She presented with hypotension, bradycardia, hypothermia, severe lactic acidosis, hyperkalaemia, and marked hyperglycaemia. Bedside echocardiography demonstrated global ventricular systolic impairment. The patient was managed with fluid resuscitation, ephedrine boluses, adrenaline infusion, treatment of hyperkalaemia, and early critical care retrieval.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Outcome</h3>\u0000 \u0000 <p>Haemodynamic stability was rapidly restored with normalisation of ventricular function within 24 h. The patient made a full recovery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights life-threatening cardiogenic shock occurring at therapeutic dosing of sustained-release verapamil in a vulnerable patient, and emphasises the importance of early physiological recognition, metabolic pattern awareness, and targeted inotropic support.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"413-417"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gerard Hawthorn BPharm, Boyd Potts BPsych (Hons), Brett Chambers BPharm, Shannon Nott BPharm, Christopher M. Doran PhD
{"title":"Modelling the return on investment of a virtual clinical pharmacy service in rural and remote Australian hospitals","authors":"Gerard Hawthorn BPharm, Boyd Potts BPsych (Hons), Brett Chambers BPharm, Shannon Nott BPharm, Christopher M. Doran PhD","doi":"10.1002/jppr.70078","DOIUrl":"https://doi.org/10.1002/jppr.70078","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The use of medication is the most common intervention in health care, with adverse drug events a leading cause of preventable healthcare harm. Increasingly, virtual pharmacy services have been implemented to support hospitals that lack the access to clinical pharmacy services to support patient safety and best practice medicines management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This research examined the potential return on investment of a virtual clinical pharmacy service (VCPS) conducted in rural and remote hospitals in New South Wales, Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>The original study adopted a stepped wedge randomised controlled trial design implemented in eight facilities. The VCPS involved clinical pharmacists providing virtual clinical pharmacy services consistent with recognised standards of practice for hospital pharmacy via videoconferencing, the electronic medical record and electronic medication management. The cost of clinical pharmacists' time to deliver services was compared with the benefit, expressed as avoided medication-related hospital admission, of pharmacist identified and physician accepted and actioned medication-related interventions stratified using the Nesbitt probability method. The return on investment (ROI) analysis modelled variations in parameters using a population of 1000 patients with 1000 simulations. Ethical approval was granted by the Greater Western Human Research Ethics Committee (Reference no: 2019/ETH13355) and the study conforms to Australian <i>National Statement on Ethical Conduct in Human Research</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 527 participants in the intervention group, with pharmacists identifying 878 medication issues and 73% of interventions accepted and actioned by the physician. The modelled return on investment of the VCPS was estimated at 20.43 (95% confidence interval [CI] 17.57, 23.30), suggesting that for every AUD $1 invested, potential savings of between $17.57 and $23.30 could be generated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The integration of virtual clinical pharmacy services into Australian rural and remote hospitals can reduce medication-related problems encountered in hospitals, leading to cost savings and improvements in patients' quality of life.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"375-382"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amina Hareem, Julie E Stevens BSc, BPharm (Hons), PhD, Joon Soo Park BPharm, PhD, Ieva Stupans BPharm (Hons), PhD, Ting-Chia Hsu PhD, Kate Wang BPharm, PhD
{"title":"Community pharmacists and telepharmacy: a narrative review of key barriers and facilitators","authors":"Amina Hareem, Julie E Stevens BSc, BPharm (Hons), PhD, Joon Soo Park BPharm, PhD, Ieva Stupans BPharm (Hons), PhD, Ting-Chia Hsu PhD, Kate Wang BPharm, PhD","doi":"10.1002/jppr.70068","DOIUrl":"https://doi.org/10.1002/jppr.70068","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose of Review</h3>\u0000 \u0000 <p>Telepharmacy has emerged as a digital extension of pharmacy services, offering remote consultations, medication reviews, and prescription verifications. While adoption has accelerated, particularly during the COVID-19 pandemic, challenges persist in community pharmacy settings. This review explored the key barriers and facilitators influencing the implementation of telepharmacy from the perspectives of community pharmacists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Source of Information</h3>\u0000 \u0000 <p>A literature search was conducted in PubMed, Embase, and CINAHL to identify original research articles published between 2014–2024. Studies were included if they examined community pharmacists' perspectives on telepharmacy, and highlighted barriers and facilitators to its implementation. Identified studies were screened, and data were extracted and grouped into themes for synthesis. This review was structured in line with key principles of the Scale for the Assessment of Narrative Review Articles (SANRA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key Findings</h3>\u0000 \u0000 <p>Eleven studies met the inclusion criteria. The most reported barriers included regulatory uncertainty, technological and infrastructural limitations, financial constraints, workload, privacy concerns, and limited digital literacy among both pharmacists and patients. Conversely, key facilitators included pharmacists' willingness to adopt telepharmacy, technical advancements, improved patient access to care, governmental support, and recognition of telepharmacy's role in public health and healthcare accessibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Telepharmacy presents a viable solution to bridging healthcare access gaps, particularly in underserved communities. However, its full integration into community pharmacy practice depends on addressing regulatory, financial, and technological barriers while building pharmacists' willingness and must be supported by government policies. Future efforts should focus on developing guidelines, standardising digital infrastructure, and providing training to equip pharmacists with the necessary skills for digital health care. Expanding telepharmacy within community pharmacies has the potential to enhance medicines management, improve healthcare accessibility, and optimise patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"365-374"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rekha Pai Mangalore PhD, Ming Gene Chai PhD, Jeffrey D. Pope PhD, Sue J. Lee PhD, Sebastian G. Wicha PhD, Arne Diehl FCICM, Trisha N. Peel PhD, Lloyd Roberts FCICM, Hans G. Schneider PhD, Adam Jenney PhD, Darshini Ayton PhD, Anton Y. Peleg PhD, Andrew A. Udy PhD
{"title":"Feasibility and fidelity of beta-lactam antibiotic therapeutic drug monitoring in critically ill adults with sepsis: a pilot randomised controlled trial","authors":"Rekha Pai Mangalore PhD, Ming Gene Chai PhD, Jeffrey D. Pope PhD, Sue J. Lee PhD, Sebastian G. Wicha PhD, Arne Diehl FCICM, Trisha N. Peel PhD, Lloyd Roberts FCICM, Hans G. Schneider PhD, Adam Jenney PhD, Darshini Ayton PhD, Anton Y. Peleg PhD, Andrew A. Udy PhD","doi":"10.1002/jppr.70087","DOIUrl":"https://doi.org/10.1002/jppr.70087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Therapeutic drug monitoring (TDM) of beta-lactam antibiotics may optimise dosing in critically ill patients with sepsis, but evidence on operational feasibility and workflow fidelity is limited. Prior trials introduced TDM later in therapy or applied constraints on dose escalation, potentially limiting the clinical impact of dose adaptation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate the feasibility and fidelity of implementing early beta-lactam TDM and TDM-guided dose adaptation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This single-centre, open-label pilot randomised controlled trial enrolled adult intensive care unit patients with sepsis within 72 h of commencing meropenem, piperacillin-tazobactam, or cefepime from June 2023–February 2024. Participants were randomised to standard of care (SOC) or early TDM-guided dosing. Trough concentrations were measured daily for up to 5 days; dose adjustments were based on predefined algorithms without upper limits on dose escalation. Primary outcomes were feasibility (recruitment rate) and fidelity (proportion of TDM delivered as intended). Secondary outcomes included target attainment and clinical outcomes. Ethics approval was granted by the Alfred Hospital Human Research Ethics Committee (Reference no: 565/22) and the study conforms with the Australian <i>National statement on ethical conduct in human research</i>. Informed consent was obtained from all patients or their substitute medical treatment decision-makers via direct approach with project information confirming their participation was voluntary and anonymous, and written consent was obtained. The study was registered with the Australian and New Zealand Clinical Trials Registry (Registration no: ACTRN12623000032651).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-two patients (TDM <i>n</i> = 22; SOC <i>n</i> = 20) were enrolled. Recruitment occurred Monday–Wednesday each week during the study period. The weekly randomisation rate was two participants. Feasibility was demonstrated with 72% of eligible patients consenting and 85.7% completing ≥3 samples. Median time from antibiotic initiation to randomisation and to first TDM was 21 h and 12 h, respectively. All dosing recommendations were accepted. Target attainment was higher with TDM (53% versus 42%). No significant differences in clinical outcomes were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Early randomisation and dose adaptation were feasible despite a weekday-limited recruitment model. TDM-guided dosing improved target","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"383-393"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Frontline care without frontline protection: why occupational violence against community pharmacists demands policy reform in Australia","authors":"Tauqeer Hussain Mallhi PhD, Yusra Habib Khan PhD","doi":"10.1002/jppr.70092","DOIUrl":"https://doi.org/10.1002/jppr.70092","url":null,"abstract":"<p>Occupational violence against community pharmacists has emerged as an increasingly recognised challenge in healthcare systems worldwide. A recent violent assault of a Melbourne pharmacist inside his own community pharmacy, in which the practitioner was reportedly punched in the face after confronting an alleged shoplifter, has once again highlighted the risks faced by community pharmacists within Australian primary care settings.<span><sup>1</sup></span> While such events are often framed as isolated criminal incidents, they may more accurately reflect a broader pattern of violence and aggression that remains insufficiently acknowledged within community pharmacy practice.<span><sup>2</sup></span> This issue warrants urgent professional discussion because, over the past decade, community pharmacists have assumed expanding responsibilities in medicine management, opioid stewardship, vaccination delivery, minor ailment care, and urgent patient triage, yet these widening clinical expectations have not always been accompanied by equivalent attention to occupational safety, legal protection, or minimum workplace security standards. It is therefore timely to consider whether the expansion of community pharmacy services has been matched by corresponding workplace safety protections.</p><p>While the assault in Melbourne may appear extraordinary in media reporting, emerging evidence suggests that violence directed at pharmacists is far from rare. A recent systematic review and meta-analysis of international studies reported that nearly half of pharmacists had experienced workplace violence, with substantial proportions reporting verbal abuse (50%), threats (42%), and physical assault (27%).<span><sup>3</sup></span> Across included studies, as many as 65% of pharmacists described experiencing at least one form of occupational violence during practice.<span><sup>3</sup></span></p><p>Community pharmacies occupy a particularly exposed position within Australian primary health care. Unlike many other healthcare settings, they are designed as highly accessible, walk-in environments with extended trading hours, unrestricted public access, and frequent face-to-face interactions between pharmacy staff and consumers. Previous literature has identified two major predictors of workplace violence in public service settings: regular contact with clients and the presence of cash or desirable goods on premises<span><sup>2</sup></span>; notably, community pharmacies fulfill both criteria simultaneously. In addition, pharmacists are frequently required to make and communicate clinically and legally appropriate decisions regarding medicine supply, including situations where requests for early opioid supply or controlled medicines cannot be accommodated, or explain stock shortages and regulatory requirements. These interactions may occasionally lead to confrontation with distressed, intoxicated, or dissatisfied consumers.<span><sup>4</sup></span> This vulnerability is comp","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"436-438"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Barras GradDipClinPharm, BPharm, PhD, FAdPha, FANZCAP (Lead&Mgmt, Research)
{"title":"Fred J Boyd 2025 oration","authors":"Michael Barras GradDipClinPharm, BPharm, PhD, FAdPha, FANZCAP (Lead&Mgmt, Research)","doi":"10.1002/jppr.70105","DOIUrl":"https://doi.org/10.1002/jppr.70105","url":null,"abstract":"<p>Firstly, I acknowledge the traditional owners of Naarm, the Wurundjeri people of the Kulin Nation. I pay my respects to Elders, past and present. I would also acknowledge the Yuggera and Turrbal people of Meanjin where I work.</p><p>Distinguished guests, family, and friends; standing here, receiving this prestigious award is an honour that fills me with gratitude and joy. Peer recognition <i>is special</i> and to be acknowledged among such skilled people is an amazing experience. I am also humbled considering the outstanding calibre of previous recipients and proud to belong to an esteemed group.</p><p>I would like to thank Paul Firman and the Queensland Branch for my nomination and Neil Cottrell and Julie Argus for being my referees. It's nice to see my mentor and Executive Director still like me…</p><p>An oration brings the pressure of imparting some profound wisdom or intriguing reflection. I pondered, procrastinated, and then for inspiration consulted that great prophet… ChatGPT… without much success.</p><p>I have elected to focus on two aspects of patient care dear to me and then reflect on what has helped me over the years. My pharmacy journey has profoundly shaped me. What started with an interest in basic pharmacology has evolved into a commitment to <i>people</i>, to <i>systems</i>, and to <i>patients</i> and the pursuit of safer, smarter and value-based care.</p><p>My first passion has been Medication Safety.</p><p>Safety work is quiet and relentless, but deeply human. Every audit, intervention, system change strives to deliver a safer experience for people facing one of the most vulnerable times of their life: a stay in and transition from a busy hospital.</p><p>It has taught me the enormous power of prevention — to quote the famous physician Don Berwick — “our contribution will be what did not happen to them”,<span><sup>1</sup></span> and the risks we identify and correct before patient harm occurs. I encourage you to ask, ‘how can this be safer?’ <i>and</i> ‘how can this be better?’ every single day. One of my current goals is to reduce medication harm at transition of care and it's great that Advanced Pharmacy Australia (AdPha) is leading work in this space.</p><p>My second passion has been clinical research.</p><p>I am often reminded that ‘standing still’ doesn't advance healthcare and progress comes from challenging assumptions and pushing boundaries. Research allows us not only to answer today's questions, but to anticipate and respond to tomorrow's needs. It's a proven investment in a future where treatments need to be more precise, outcomes more predictable and patient care personalised and equitable. I have been fortunate to be employed as a University Research Conjoint one day/week for the past 12 years. This has enabled me to lead a department, pursue research, and mentor many exceptional pharmacists. It's great to see AdPha re-energising their vision and support for research via new strategies and scholarships.</p><p>Bot","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"439-441"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah Amin Abou-El-Makarem MClinPharm, FANZCAP (Neonatol., ObsGynae), Mohamed Shaaban MClinPharm
{"title":"Combination of cervical cerclage and vaginal progesterone for prevention of preterm birth in singleton pregnancy with a short cervix: a scoping review","authors":"Sarah Amin Abou-El-Makarem MClinPharm, FANZCAP (Neonatol., ObsGynae), Mohamed Shaaban MClinPharm","doi":"10.1002/jppr.70100","DOIUrl":"https://doi.org/10.1002/jppr.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Women with a short cervix are at increased risk of preterm birth (PTB), a major contributor to neonatal morbidity and mortality globally, leading to significant financial and emotional burdens for families and healthcare systems. Cerclage or vaginal progesterone is effective for reducing PTB, but the benefits of combining both interventions remain unclear and nonconclusive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This scoping review aimed to critically appraise current evidence on the effectiveness of combining cerclage and vaginal progesterone in managing short cervix in singleton pregnancies to prevent PTB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>PubMed and Embase were searched for studies published between 2018–2024. The authors independently performed screening and data extraction. Studies that included singleton pregnancies with short cervix (defined as cervical length <25 mm) and comparing combination therapy (cerclage and vaginal progesterone) versus either intervention alone were included. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) guidelines and applied the Arksey and O'Malley framework.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 923 studies were identified and 12 studies were included. Most studies had a retrospective design (<i>n</i> = 10). Combination of cerclage and vaginal progesterone showed a trend towards improved maternal and neonatal outcomes, including prolonging pregnancy period particularly in high-risk populations with cervical length ≤10 mm; however, five studies did not demonstrate statistically significant benefits.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review highlighted the need for larger, well-designed studies to evaluate the efficacy and cost-benefit analysis of cerclage and vaginal progesterone in the prevention of PTB in singleton pregnancies with short cervix as compared to either intervention alone.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"353-364"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. S. Wong BPharm, Y. Wang BSc, MSc, PhD, X. Y. Lim BPharm (Hons), MPharmSce, J. Hikaka BPharm, PhD, S. Scahill BPharm, MMgt, PhD, B. van der Werf Drs Biology, D. J. Exeter BA, MA, PhD, M. Hudson BPharm, A. Nu'u BPharm, S. S. Ram BPharm, LLB, PhD
{"title":"Understanding conscientious objection among pharmacists in New Zealand","authors":"L. S. Wong BPharm, Y. Wang BSc, MSc, PhD, X. Y. Lim BPharm (Hons), MPharmSce, J. Hikaka BPharm, PhD, S. Scahill BPharm, MMgt, PhD, B. van der Werf Drs Biology, D. J. Exeter BA, MA, PhD, M. Hudson BPharm, A. Nu'u BPharm, S. S. Ram BPharm, LLB, PhD","doi":"10.1002/jppr.70073","DOIUrl":"https://doi.org/10.1002/jppr.70073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Conscientious objection (CO) recognises healthcare practitioners' freedom of conscience but can impact equitable access to services. There is limited research in understanding CO among pharmacists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To investigate CO among pharmacists in New Zealand, including support for and factors influencing CO decisions in providing various medicines and services, and attitudes towards benefits and concerns associated with CO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A cross-sectional, anonymous online survey was conducted among 294 registered pharmacists in New Zealand. Fisher's exact test and regression analyses were performed to assess and associate participants' demographics with responses to support for CO, prevalence of CO, and qualitative questions. Thematic analysis was used to explore the qualitative findings on benefits and concerns about CO. Ethical approval was granted by the University of Auckland Human Participants Ethics Committee (Reference no: UAHPEC26360) and the study conforms with the Declaration of Helsinki. Informed consent was obtained from all participants via distribution of project information indicating participation was voluntary and anonymous.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Approximately two-thirds of participants (<i>n</i> = 195, 66.3%) supported pharmacists' right to CO, although the majority (<i>n</i> = 252, 85.7%) reported no experience with CO. When asked about willingness to supply medicines, participants most frequently objected to medical abortifacient medicines, the emergency contraceptive pill, and gender-affirming hormone therapy. Participants with a religion were more likely to support CO (odds ratio [OR] 3.83, 95% confidence interval [CI] 2.25, 6.54, p < 0.001) while age (51–60 years) and religion appeared to be associated with a higher CO prevalence (Age adjusted OR 7.06, 95% CI 2.25, 22.16, p < 0.001; Religion adjusted OR 6.99, 95% CI 1.42, 34.37, p = 0.017).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings suggest the majority of New Zealand pharmacists support CO and will practice CO in line with the New Zealand Code of Ethics for pharmacists in ensuring continuity of care. Future research should specifically explore the impact of rurality on access to pharmacies and service disparities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"403-412"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hatsumi Kobayashi BPharm (Hons), MPharm, Jeremy Szmerling BPharm (Hons), ANZCAP-Reg. (PainMgmt, Steward.), Sam Maleki BPharm, MPharmPrac, Mahisha Thiruvasagan BPharm, MPharmPrac, Gordon Mar MMed, FANZCA
{"title":"Evaluation of the acceptance rate of analgesic stewardship team recommendations at a metropolitan hospital network","authors":"Hatsumi Kobayashi BPharm (Hons), MPharm, Jeremy Szmerling BPharm (Hons), ANZCAP-Reg. (PainMgmt, Steward.), Sam Maleki BPharm, MPharmPrac, Mahisha Thiruvasagan BPharm, MPharmPrac, Gordon Mar MMed, FANZCA","doi":"10.1002/jppr.70081","DOIUrl":"https://doi.org/10.1002/jppr.70081","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Analgesic stewardship (AGS) programs, a novel concept in Australia, aim to assess and optimise opioid and other analgesia by carrying out medication reviews and providing clinical recommendations to the treating teams.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to determine the rate and extent of acceptance of AGS team recommendations among adult inpatients within a metropolitan hospital network.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This 12-month retrospective study included patients admitted to an acute hospital within an approximate 1500-bed hospital network between 1 January–31 December 2023. Patients were included if they had at least one AGS progress note documented during their hospital stay. Quantification of AGS recommendations, evaluation of recommendation outcomes, and comparison of recommendation acceptance against hospital site, medical unit, and patient demographics were conducted. Patients for whom none of the AGS recommendations were accepted were analysed thematically. This project was exempt due to the local policy requirements that constitute research by the Eastern Health Research Ethics Committee (Reference no: QA24-056-109 074). The justification for this exemption was as follows: the project only was retrospective, utilised routinely collected data, and the study conforms with the Australian <i>National statement on ethical conduct in human research</i>. [Correction added on 3 November 2026, after first online publication: The preceding sentence has been corrected in this version.]</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2047 AGS recommendations were identified across 901 patients (median age 78 years, range 18–105, 61% female), with a median of two recommendations per patient (interquartile range 2–3). For 620 patients (69%), all recommendations were implemented. The most common reason for non-acceptance was recommendations being missed by the treating team. Recommendations made at the largest hospital site by bed number were associated with higher acceptance (odds ratio [OR] 1.93, 95% confidence interval [CI] 1.37–2.73). Acceptance was also higher for surgical units (OR 2.02, 95% CI 1.35–3.01), corresponding to approximately double the odds, than for non-surgical units. Younger adult patients (aged <65 years) had higher odds of recommendation acceptance than those aged ≥65 years (OR 1.65, 95% CI 1.07–2.55).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 ","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"56 5","pages":"394-402"},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149331576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}